Rhumbline Advisers Has $9.13 Million Stock Holdings in Innospec Inc. (NASDAQ:IOSP)

Rhumbline Advisers decreased its holdings in shares of Innospec Inc. (NASDAQ:IOSP) by 0.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 73,873 shares of the specialty chemicals company’s stock after selling 253 shares during the period. Rhumbline Advisers’ holdings in Innospec were worth $9,130,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of IOSP. TFO Wealth Partners LLC raised its holdings in shares of Innospec by 29,800.0% in the fourth quarter. TFO Wealth Partners LLC now owns 299 shares of the specialty chemicals company’s stock valued at $37,000 after purchasing an additional 298 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Innospec in the first quarter valued at about $66,000. CWM LLC raised its holdings in shares of Innospec by 239.6% in the second quarter. CWM LLC now owns 635 shares of the specialty chemicals company’s stock valued at $78,000 after purchasing an additional 448 shares during the last quarter. Motco purchased a new stake in shares of Innospec in the first quarter valued at about $132,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Innospec in the first quarter valued at about $147,000. Institutional investors and hedge funds own 96.64% of the company’s stock.

Innospec Stock Performance

IOSP opened at $106.55 on Friday. The firm has a market cap of $2.66 billion, a P/E ratio of 18.09 and a beta of 1.08. The firm has a 50-day moving average of $117.40 and a 200 day moving average of $122.45. Innospec Inc. has a fifty-two week low of $95.69 and a fifty-two week high of $133.71.

Innospec (NASDAQ:IOSP) last posted its quarterly earnings results on Tuesday, August 6th. The specialty chemicals company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.37 by $0.02. The company had revenue of $435.00 million during the quarter, compared to analyst estimates of $468.73 million. Innospec had a net margin of 7.90% and a return on equity of 14.15%. The firm’s revenue for the quarter was down 9.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.28 earnings per share. Equities research analysts predict that Innospec Inc. will post 5.95 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded shares of Innospec from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 8th.

Insider Activity at Innospec

In related news, CFO Ian Cleminson sold 3,398 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $114.74, for a total transaction of $389,886.52. Following the completion of the transaction, the chief financial officer now owns 12,996 shares in the company, valued at $1,491,161.04. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.52% of the stock is owned by company insiders.

Innospec Company Profile

Innospec Inc develops, manufactures, blends, markets, and supplies specialty chemicals in the United States, rest of North America, the United Kingdom, rest of Europe, and internationally. The company's Fuel Specialties segment offers a range of specialty chemical products that are used as additives in additives in diesel, jet, marine, fuel oil and other fuels.